Investing in Aurinia Pharmaceuticals Inc (AUPH)  ➔  Intrinsic value

Prev. close$11.29 
Previous Close$11.29  
Valuation MethodValuePotential 
Chepakovich Model$2.69-76%recalculate
Graham Formula$0.00-100%recalculate

Latest news

10 May

Better Days Are on the Horizon for Aurinia Stock, Says Analyst => TipRanks 5:47PM

Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis => Business Wire 4:05PM

Aurinia Pharma's Stock Gains After Lupkynis Data From Late-Stage Lupus Nephritis Study Published In Lancet => Benzinga 6:53AM

Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet => Business Wire 6:05AM

6 May

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Misses Revenue Estimates => Zacks 7:45PM

Why Aurinia Pharmaceuticals Stock Is Crashing Today => Motley Fool 5:33PM

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights => Business Wire 4:05PM

Aurinia Pharmaceuticals, Inc. to Host Earnings Call => ACCESSWIRE 3:15PM

28 Apr

Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021 => Business Wire 6:30AM

26 Apr

Is AUPH Stock A Buy or Sell? => Insider Monkey 6:59AM

15 Apr

Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference => Business Wire 6:05AM

8 Apr

Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows => Benzinga 7:38AM

Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings => Business Wire 6:05AM

31 Mar

When Can We Expect A Profit From Aurinia Pharmaceuticals Inc. (TSE:AUP)? => Simply Wall St. 1:36AM

15 Mar

3 Favorite Names With Exciting Potential => 8:52AM

Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report => Business Wire 6:05AM

11 Mar

Aurinia Pharmaceuticals: Short-Term Trading of a Long-Term Favorite => 7:45AM

2 Mar

Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences => Business Wire 6:05AM

25 Feb

Aurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call Transcript => Motley Fool 12:00AM

24 Feb

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights => Business Wire 4:02PM

Aurinia Pharmaceuticals, Inc. to Host Earnings Call => ACCESSWIRE 2:30PM

23 Feb

Earnings Preview: Aurinia Pharmaceuticals => Benzinga 10:29AM

18 Feb

Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference => Business Wire 6:05AM

17 Feb

Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021 => Business Wire 6:05AM

14 Feb

We're Not Worried About Aurinia Pharmaceuticals' (TSE:AUP) Cash Burn => Simply Wall St. 2:08AM

11 Feb

Orea Reports that French Government has Announced Appeal of Court Decision to Renew the Montagne d'Or Mining Concessions => CNW Group 5:30PM

1 Feb

Shark Bites: Anatomy of a Trade - Aurinia Pharmaceuticals => 7:45AM

27 Jan

Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates => Zacks 11:05AM

Here's Why Everybody's Talking About Aurinia Pharmaceuticals Stock => Motley Fool 6:27AM

26 Jan

The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market => Benzinga 8:07AM

25 Jan

Why Aurinia Pharmaceuticals Stock Is Flying Today => Motley Fool 4:22PM

Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis => Zacks 10:34AM

Aurinia’s Kidney Disease Treatment Wins FDA Approval; Street Sees 78% Upside => SmarterAnalyst 6:53AM

22 Jan

FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis => Business Wire 8:24PM

11 Jan

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options => Zacks 9:56AM

8 Jan

Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences => Business Wire 6:05AM

2 Jan

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates => Benzinga 10:45AM

30 Dec

My Top Six 2020 Stock Picks Gained an Average of 75% => 11:08AM

28 Dec

Aurinia (AUPH) Looks Good: Stock Adds 5.5% in Session => Zacks 8:32AM

21 Dec

Is AUPH A Good Stock To Buy According To Hedge Funds? => Insider Monkey 3:40PM

Company description

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.